Key clinical point: Pimavanserin (Nuplazid) may be useful in patients with dementia-related psychosis.

Major finding: In responders to a 12-week, open-label treatment phase, the drug reduced the risk of psychosis relapse by almost 200% by the end of the next 26 weeks

Study details: The two-phase study enrolled 392 patients into a 12-week, open-label portion, after which 191 responders entered a randomized, 26-week phase.

Disclosures: Acadia Pharmaceuticals sponsored the study. The presenter is an employee of the company.